


GE Healthcare



Welcome
Dan Janki

RSNA Investor Meeting
November 30, 2006



imagination at work

"This document contains 'forward-looking statements' - that is, statements related to future, not past, events. In this context, 'forward-looking statements' often address our expected future business and financial performance, and often contain words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' or 'will.' 'Forward-looking statements' by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements."

Today's agenda


11:00 – 11:30	Arrivals and Lunch
11:30 – 11:45	Welcome and Introduction
	- Dan Janki
	- Joe Hogan
11:45 – 1:45	GE Healthcare Booth Tour
2:00 – 4:00	GE Healthcare – Winning Today, Winning Tomorrow
4:00 – 4:30	Q&A



imagination at work

PAGE 2
GE Healthcare RSNA
November 30, 2006

GE Healthcare: Summary



Joe Hogan
President & CEO, GE Healthcare

RSNA Investor Meeting
November 30, 2006



imagination at work

"This document contains 'forward-looking statements' - that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance, and often contain words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' or 'will.' Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties which could adversely or positively affect our future results include: the behavior of financial markets, including fluctuations in interest rates and commodity prices; strategic actions, including dispositions; future integration of acquired businesses; future financial performance of major industries which we serve, including, without limitation, the air and rail transportation, energy generation, media, real estate and healthcare industries; unanticipated loss development in our insurance businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business, competitive and regulatory nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements."

What you will see today

Breakthroughs 5-10 years out

GE Science and Technology Center

Leadership in molecular imaging

Discovery VCT

Hawkeye 4

Molecular imaging agents

Product innovations across all businesses

LightSpeed VCT XT

Signa HDX 3T

LOGIQ ultrasound family

Innova 3100

Senographe Essential

iDXA

Digitization

Centricity product line

Customer Engagement

"Expert bars"



imagination at work

GE Healthcare RSNA
November 30, 2006

GE Healthcare: Growth through the transformation of healthcare



Joe Hogan
President & CEO, GE Healthcare

RSNA Investor Meeting
November 30, 2006



imagination at work

A collage of various medical and scientific images. It includes MRI scans of a brain and a heart, a DNA double helix, a heart, a microscope, a laboratory setting, and various other medical equipment and biological structures. The images are arranged in a grid-like fashion around the central text.

Only GE Healthcare

- Information Technology
- Broad-based Diagnostics
- Molecular Imaging
- Life Sciences


Delivering three complementary, technology platforms

Information Technology & Services




- Electronic med records
- PACS
- Performance solutions
- Multi-vendor services

Life Sciences




- Discovery systems & tools
- Protein and cell sciences

Broad-based Diagnostics



Diagnostic Imaging

CT, PET/CT
MR, XR



Medical Diagnostics

Contrast agents
Molecular
diagnostics



Clinical Systems

Ultrasound
Critical care

Creating new opportunities, serving healthcare customers, positioned for growth




imagination at work

PAGE 7
GE Healthcare RSNA
November 30, 2006

GE Healthcare

Revenue (\$ in billions)



New technologies
+
market understanding
= growth

How we win

- ✓ Industry-leading technology
- ✓ Unmatched global, product and services reach
- ✓ World-class execution and process rigor
- ✓ Growth through disease focus
- ✓ Success in emerging markets
- ✓ Delivering clinical efficacy and efficiency

Positioned for continued growth



imagination at work

PAGE 8
GE Healthcare RSNA
November 30, 2006

GE Healthcare in 2006: delivering

Strategic Goals

Accomplishments

Accelerate disease focus

- ✓ Neuro: launch DATSCAN for DLB & Alzheimer's*
- ✓ Onco: launched Hexvix for bladder cancer*
- ✓ Opened clinical trials dev't center in India

Leading products

Lead Healthcare IT

- ✓ Leadership in EMR: closed IDX
- ✓ UK's #1 PACS supplier
- ✓ Building IT infrastructure with Intermountain Health

Growing IT footprint

Drive new markets

- ✓ Protein Science: acquired leading capabilities
- ✓ Cell analysis and therapy
- ✓ Alzheimer's: several Rx and academic partnerships

Seizing leadership

Innovate

- ✓ Launch of new series of portable ultrasounds
- ✓ Launch of VCT/PET for cardio/onco applications
- ✓ Exceeded 1000 installs of the LightSpeed VCT

Setting industry standard

Win with customers


- ✓ Constant improvements in product/service quality
- ✓ Enterprise sales leadership, NPS customer focus

Putting customers first

* Not in the US

Driving global growth

Revenue (\$ in billions)



imagination at work

\$4B growth in 6 years

PAGE 10
GE Healthcare RSNA
November 30, 2006

Our Vision: Healthcare Re-imagined

We are striving to transform the delivery of healthcare.

Our Purpose is to help **predict**, **diagnose**, **treat** and **monitor** disease earlier so people can live life to the fullest

From

"Late Disease"

- ✓ Symptom-based
- ✓ Incomplete data
- ✓ Managing illness
- ✓ Standardized treatment

To

"Early Health"

- ✓ Prevention/prediction
- ✓ Detailed patient info
- ✓ Early diagnosis
- ✓ Targeted therapies

Driving clinical efficacy & healthcare system efficiency




Imagination at work


PAGE 11
GE Healthcare RSNA
November 30, 2006

Outstanding performance in a strong field


Revenue growth 2003 - 2006E CAGR




Revenue 2006E




EBIT 2006E



EBIT growth 2003 - 2006E CAGR



The economics of 'Early Health'




Key drivers ... why now?

- **Technology** ... advances and costs **Enable** it
- **Economics** ... healthcare systems **Require** it
- **Demographics** ... baby boomers **Demand** it


Meeting healthcare needs

- Transparency of cost
- Quality of healthcare
- Early health, earlier diagnosis
- Increasing productive lifespan
- Equity in healthcare access


GEHC: strong foundation driving the transformation of disease management



GEHC: strong foundation driving the transformation of disease management






Dx spending shift: the industry opportunity



The diagnostic impact on cardiac care

Imaging critical at each stage of cardiac management

Disease state	At-risk asymptomatic	Moderate	Severe
Indicators	Lipid assessment Calcium score Risk factors	Cardiac function Perfusion & viability Coronary anatomy	Viability Innervation
GE offerings	 U/S IMT EKG	 Optison U/S VCT Visipaque Cath	 Innova IVUS Ultrasound TSI TWA/HRT algorithm
GE development	Vulnerable Plaque SPECT Gender Specific EKG IDXA body fat assessment	Myoview Dual Isotope Visipaque + VCT Omniscan CMR	Early CHF SPECT remodelling Remote monitoring AdreView Spect
Therapy	Medical therapy Lipid reducers Behaviour change	CABG PCI	Surgical ICD/ CRT/ LVAD Transplantation
Costs	Early: treating risk factors \$1K-\$2K/yr	Moderate: angina ~\$12K Mid-Late: PMI \$18-40K	Transplant & immuno suppresants \$200K +

Earlier diagnosis = more treatment options,
better outcomes and economics

Source: J&J Research, October 2005


The diagnostic impact on breast cancer

Imaging critical to cancer management and treatment today

Predict	Genetic assessment: BRCA1/2, HER2
Diagnose	Digital Mammography + CAD for breast cancer screening
Diagnose	MR to assess extent of disease
Treat	Ultrasound or Mammo for wire localization (surgical planning)
Treat	Image guidance for radiation therapy (6 treatments)
Monitor	PET/CT to assess response to treatment
Monitor	Ongoing annual screening

Explosive Growth
in DX procedures


Growth in number of breast cancer imaging procedures in US



New DX technologies driving growth

Sophisticated diagnostics transforming neurology

Neurological conditions growing as cancer and CV death rates fall...



Today: GE leading in major neuro indications

Alzheimer's		PiB Alzheimer's development compound	GE Exclusive
Lewy Body		DaTSCAN	GE Exclusive
Parkinson's Disease		DaTSCAN	GE Exclusive
MR Motion Correction		PROPELLER	GE First



Imagination at work

Neurology: the next multi \$B market

Sources: MJG Epidemiology Database, AHA, CDC

PAGE 19
GE Healthcare RSNA
November 30, 2006

Industrialization of next generation diagnostics: FASTlab

Amersham brought

- Research
- Process chemistry
- Radio Rx development
- Quality Assurance
- Regulatory



"FASTlab's cassette-based mechanism and ease...brings turn-key production of PET tracers closer"

MayoClinic.com

Prof. Lowe, PET facility

GE Medical brought

- Six Sigma
- Engineering
- Cyclotron expertise
- PET experience

What it means...

- ✓ GE industrializing PET chemistry and Molecular Imaging
- ✓ Speeds evolution of cancer, cardiovascular and neurological research/ drug development
- ✓ Enables PET diagnostics to be more accessible to patients
- ✓ Successfully tested: US/European commercial/academic sites
- ✓ cGMP compliance easier to achieve



Cassette designed for future PET imaging agents

Exclusive technology...opening the door to consistent and predictable Molecular Imaging

GE Healthcare

(\$ in billions)

5-10% Revenue
15-20% OP



How we win

- ✓ Industry leading technology
- ✓ Unmatched global, product and services reach
- ✓ World class execution and process rigor
- ✓ Growth through disease focus
- ✓ Success in emerging markets
- ✓ Delivering clinical efficacy and efficiency

Uniquely positioned ... diversified Healthcare business



imagination at work

PAGE 21
GE Healthcare RSNA
November 30, 2006

Today's speakers

Mark Vachon, President & CEO, Diagnostic Imaging

Dan Peters, President & CEO, Medical Diagnostics

Omar Ishrak, President & CEO, GE Healthcare Clinical Systems

Reinaldo Garcia, President & CEO, International

Vishal Wanchoo, President & CEO, GE Healthcare IT

Nigel Darby, Head of R&D, Life Sciences

Bill Clarke, Chief Technology & Medical Officer



imagination at work

PAGE 22
GE Healthcare RSNA
November 30, 2006


Diagnostic Imaging: Winning today and tomorrow



Diagnostic Imaging: great technology, positioned for growth

(\$ in billions)


Global revenue



Key messages

- ✓ Strong markets ... robust procedure growth
- ✓ Continued ability to drive customer value
- ✓ Driving specificity and sensitivity to change healthcare paradigm
- ✓ Using technology to integrate diagnostics and therapy
- ✓ Leading Service capability
- ✓ Cultural commitment to productivity and quality funding growth

Global procedures growing




imagination at work

Source: HIMAP, AMR, Bio-tech Systems, Medtech insight

PAGE 25
GE Healthcare RSNA
November 30, 2006

Evolving and winning in growing market



imagination at work


*US: NEMA 2006

PAGE 26
GE Healthcare RSNA
November 30, 2006

X-Ray Re-imagined

Digital transformation driving market explosion

Market \$B



- ✓ 70% of all DI procedures
- ✓ Huge customer base...95K US only
- ✓ Globally 3 million exams every day




Imagination at work

Source: Frost and Sullivan

GE positioned to win

- ✓ Leading brand
- ✓ Complete product portfolio
- ✓ Detector technology
- ✓ Ease of use and workflow
- ✓ Advanced applications
- ✓ Service depth

X-Ray for screening
... Early detection




PAGE 27
GE Healthcare RSNA
November 30, 2006

Changing cardiac standard of care

Diagnosing in 1995

- Chest pain / Heart attack
- EKG / Diagnostic Cath
- MPI-SPECT
- U/S anatomy & function




Treating in 1995

- Bypass procedure
- Transplant
- Pacemaker
- Drug therapy



Diagnosing today

- Biomarkers
- U/S Carotid IMT
- Cardiac CTA
- Nuclear stress
- Gated MPI/SPECT
- U/S TSI, IVUS, ICE
- Remodelling imaging




Treating today

- Statins, inhibitors
- Drug Eluting Stents
- Prosthetic Heart Valves
- EP Ablation
- Heart assist devices
- Internal defibrillators



GE revenue growth in cardio



New GE cardio innovation

VCT XT	5 beat heart...70% less dose
UltraFast SPECT	SNM image of the year
Agents	Myoview, Visipaque, AdreView studies
Apps	Card IQ, VCAR, Vessel IQ Express fusion
U/S Cardiac	Leading global position

Changing cardiac standard of care: VCT

Cardiac CTA
Routine clinical reality

2006

Imagination
Breakthrough

5-Beat Cardiac...↓70% dose
~\$1.5B revenue

Changing breast cancer standard of care

Diagnosing in 1995

- Analog mammography
- Ultrasound
- Stereotactic biopsy

Standard of care 1995:

- Late detection/few treatments
- Limited patient stratification
- Invasive/radical treatment
- Higher treatment morbidity

Treatment options:

- Radical mastectomy
- Traditional chemo
- Tamoxifen

Diagnosing today

- BRCA 1/2
- Digital Mammo + CAD
- 3D Ultrasound
- Breast MRI
- PET/CT
- HER2 status

Standard of care today:


- Earlier detection ++ options
- Less invasive
- Greater patient stratification
- Improved drug +/- profile
- Side effect monitoring
- Reduced morbidity

Treatment options

- Lumpectomy
- Image-guided radiation therapy
- Targeted: Herceptin®, Avastin®
- New chemos: taxanes
- Sequential hormone therapies: Tamoxifen, Aromatase inhibitors

GE wins:

Revenues \$MM




Only GE:

- ✓ Senographe Digital Mammography
- ✓ MR VIBRANT with spectroscopy
- ✓ 3D Ultrasound imaging
- ✓ Personalized breast cancer management

Changing breast cancer standard of care

GE pioneers full field digital mammography


1995



- Lower sensitivity: young women
- Impersonal – no tech in room
- 2% - 3% retakes
- Physical film archival
- High dose (2.4 mS)













Only 11%
of systems
are digital

- 15% better sensitivity: women <50
- Personalized – tech stays in room
- Sharp image contrast
- Less retakes
- Electronic archival
- 28% lower dose (1.7 mS)




... and 2X Productivity!

Driving Molecular Imaging

Disease	Target	GE MDX agents	GE DI Technologies	Applications
Alzheimer's \$500MM		PiB 		PET/CT Diagnose Alzheimer's track therapy
Congestive heart failure \$300MM		Adreview 		Cardiac Nuclear Image cardio-vascular neurotransmission network
Prostate cancer \$350MM		¹³ C 		¹³ C MR Image cancer cell metabolism
Parkinson's dementia \$250MM		Striataview 		Nuclear Head Increase diagnosis sensitivity

Only GE: agents + hardware + software

Services moving beyond maintenance



Differentiating customers' experience

- #1 IMV ...CT, MR, PET
- Managing the total asset lifecycle
- Lean driving cycle time ↓ 30% in service delivery
- Pervasive broadband
 - >20K assets
 - ↑ 20% remote fix

Beyond maintenance to solution

- Asset management: utilization, tracking, planning
- Performance Solutions: clinical and radiology workflow
- Adjacencies: Education Services
Hospital of the Future




imagination at work

PAGE 33
GE Healthcare RSNA
November 30, 2006

Lean... capacity for growth

Inquiry to Order




- Lean**
- 141 → 34 Configs
 - 17 → 5 PDA Forms
 - ↓ 47% Price points

Customer

Customer Trans
↓ 40%


Installation



- Design 14 → 4 days
- Backlog 254 to 0
- 92 → 1 Tracker

↓ 1 Day Install =
\$10K Cust Revenue


First Response



- 26 → 3 min answer
- 30 → 15 min page

Patient Reschedules
Reduced 2/Event

Service Delivery



- 58 → 72% parts ship in 4 hrs
- Diagnose 14 to <5min

Patient Throughput
+180 CT Exams



imagination at work

PAGE 34
GE Healthcare RSNA
November 30, 2006

Things to like in Diagnostic Imaging



Key messages

- ✓ Strong markets ... robust procedure growth
- ✓ Continued ability to drive customer value
- ✓ Driving specificity and sensitivity to change healthcare paradigm
- ✓ Using technology to integrate diagnostics and therapy
- ✓ Leading Service capability
- ✓ Cultural commitment to productivity and quality funding growth

GE Healthcare: a world-class Medical Diagnostics business



Dan Peters
President & CEO, Medical Diagnostics

RSNA Investor Meeting
November 30, 2006



imagination at work

Medical Diagnostics: setting the industry standard

(\$ in billions)



Key messages

- ✓ Global leadership, scale, distribution
- ✓ Early detection: oncology, cardiology, neurology, urology
- ✓ Unique and novel compounds
- ✓ World-class R&D: accelerated clinical trial program
- ✓ Manufacturing excellence/regulatory
- ✓ One new imaging agent per year



Imagination at work

PAGE 37
GE Healthcare RSNA
November 30, 2006

Evolution of imaging agent growth




Social

- Aging population
- Obesity, diabetes and heart disease prevalence
- Image-guided interventions replacing invasive biopsies/ surgeries
- Payers demanding proof of efficacy

Scientific

- Increased specificity and sensitivity of diagnostics
- Growth of molecularly targeted therapeutics- needing imaging for efficacy monitoring
 - Gleevec, Herceptin, Tarceva, Iressa

X-Ray procedures/million inhabitants (US, 2002)



- Over 50s 28% of population today but 67% of X-Ray
- 71MM \geq 65 in US 2030

Pre-symptomatic screening to monitoring

Global presence across disease states and modalities

Market leadership

- #1 Overall across all modalities
- #1 Nuclear Segment
- #1 X-Ray Contrast
- #2 MRI Contrast



imagination at work

Disease area

Cardiology

Visipaque
Omnipaque

Omniscan

Myoview
Adreview

Fastlab

Oncology

Visipaque
Omnipaque

Omniscan

Hexvix

Myoview
Adreview

Fastlab
Angiogenesis

Neurology

Visipaque
Omnipaque

Omniscan

Striataview

Fastlab
PIB

Urology

Visipaque
Omnipaque

Omniscan

Hexvix

Americas

X-Ray/CT MRI Optical SPECT PET

* Development

PAGE 39
GE Healthcare RSNA
November 30, 2006

Global presence across disease states and modalities

Market leadership

- #1 Overall across all modalities
- #1 Nuclear Segment
- #2 X-Ray Contrast
- #2 MRI Contrast



imagination at work

Disease area

Cardiology

Visipaque
Omnipaque

Omniscan

Myoview
Adreview

FDG
Fastlab

Oncology

Visipaque
Omnipaque

Omniscan

Hexvix

Myoview
Adreview

FDG
Fastlab
Angiogenesis

Neurology

Visipaque
Omnipaque

Omniscan

DatSCAN

FDG
Fastlab
PIB

Urology

Visipaque
Omnipaque

Omniscan

Hexvix

Europe/Asia/Japan

X-Ray/CT MRI Optical SPECT PET


* Development

PAGE 40
GE Healthcare RSNA
November 30, 2006

MDX: driving growth in existing products

Life cycle management key to growth: numerous GEHC bets

Sales
(\$B)



2007: Examples of new indications

Product	New Indication
 <small>ISOMOLAR VISIPAQUE™ (GADOLINUM) INJECTION</small>	✓ Nephric II
	✓ CT CIN
	✓ Cardio dynamics
	✓ CTA coronary
 <small>OMNIPAQUE™ (IOPAMIDE) INJECTION</small>	✓ CT colonography
 <small>MYOVUE™ Sodium Thallous Chloride</small>	✓ Outcomes
	✓ Dual isotope
 <small>DaTSCAN™ L-Dopa</small>	✓ Dementia with Lewy Bodies

Annual Revenue
Potential ~\$5B




PAGE 41
GE Healthcare RSNA
November 30, 2006

GE: robust pipeline of new imaging agents

Annual revenue potential ~\$1B

New product	What it does	Modality	Disease area	Anticipated launch
Hexvix	Diagnose Bladder Cancer	Optical	Oncology	✓ 2006: Europe 2008: RoW
Sonazoid	Detect Liver Metastases	Ultrasound	Oncology	2007: Japan
Fast Lab/ SteriPET	For manufacture of PET cancer agents	PET	Oncology	2007: Europe
AdreView	Oncology: neuroblastoma Cardio: sudden cardiac death risk stratification	SPECT	Oncology Cardiology	2007: Europe 2008: US
Striataview	SPECT/Parkinsonian Syndrome	SPECT	Neurology	2009: N. Am
Angiogenesis PET agent	Breast Cancer	PET	Oncology	2010: US
PiB	Diagnose Alzheimer's	PET	Neurology	2010: Europe & US

Driving growth in coronary artery disease

	Pre-clinical disease 65MM	Symptomatic CAD 15MM	Heart failure 5MM
US patient population			
GE bet	Visipaque + VCT	'Dual Isotope' validation	Predicting heart failure
What it does	Creating a new routine, recurring cardiac diagnostic procedure* 	Improve diagnostic operational efficiencies via faster throughput* 	Identifies at risk patient for sudden cardiac death* 
CAD stats	38% of all deaths US 49% of all deaths Europe	Risk of CAD after age 40 ♂ 32% ♀ 49%	50% ♂ who die of CAD have no symptoms 63% ♀
Potential sales	\$100MM	\$50MM	\$160MM


* Application not FDA approved

Driving growth in neurology


Opportunity
Improve the diagnosis of Parkinson's

GE bet
DaTSCAN: launched in Europe for Parkinson's and dementia diagnosis
StriataView: to launch in North America by 2009

DaTSCAN
COLLUMABE (TM)




Growth potential
DaTSCAN and StriataView Imaging Market (\$MM)




Opportunity
Improve the diagnosis of Alzheimer's

GE bet
Alzheimer's PET diagnostic
PiB: Molecular Imaging agents help diagnose Alzheimer's Disease



Growth potential
Population aging
US 65+ population (% of total)



GE Today: joint development of Rx and Dx




Entering a new modality 2006: optical imaging/urology

Opportunity

Bladder cancer diagnosis
5th most prevalent cancer
Most expensive cancer
High recurrence

GE new product launch


First, in-class agent for early diagnosis of superficial bladder cancer
Detected 30% more patients with bladder; 67% more CIS lesions
Improved treatment in 1 in 5 patients
Strong potential to reduce recurrence and progression



Hexvix imaging
bladder cancer tumor

Growth potential


Launched in Europe 2006
Developing for US and other markets 2008



Imagination at work


PAGE 45
GE Healthcare RSNA
November 30, 2006

GE's imaging agent development network



Medical Diagnostics: why we'll continue to win

- ✓ Global leadership, scale, distribution
- ✓ Early detection: oncology, cardiology, neurology, urology
- ✓ Unique and novel compounds
- ✓ World-class R&D: accelerated clinical trial program
- ✓ Momentum via hardware, software, agent collaboration
- ✓ One new imaging agent per year



PAGE 47
GE Healthcare RSNA
November 30, 2006

Clinical Systems: new approaches for the world's patients




Omar Ishrak
President & CEO, Clinical Systems

RSNA Investor Meeting
November 30, 2006



Clinical Systems: winning through innovation and market segmentation

(\$ in billions)



Key messages

- ✓ Strong product management
- ✓ Technology leadership
- ✓ Clinical expertise
- ✓ Focused distribution

Margin expansion

Continuous share gain



imagination at work

PAGE 49
GE Healthcare RSNA
November 30, 2006

Clinical Systems business overview



Ultrasound

Cardiology

Monitoring

Bone
Densitometry

Maternal
Infant Care

Life
Support


- ✓ Point of care technologies
- ✓ Spans the entire continuum of care
- ✓ Unique portfolio of market leaders
- ✓ The "Front Door" to early health



imagination at work

PAGE 50
GE Healthcare RSNA
November 30, 2006

Trends and opportunities




Today: Growth via broad market footprint
Tomorrow: Every dept, disease & patient → GEHC tech convergence

Clinical Systems growth strategy




Sustained growth in ultrasound

Extending broad leadership position



2005 global market share (\$5.3B Mkt)



Source: Klein Biomedical and internal Equipment and service

Winning in major mkts

Clinical focus & expertise
Annual breakthroughs
3X segment growth in 2006

Winning in compact

Miniaturization "big bet"
5 new products in 2006
#1 in 2006... + 10 pts share

Winning in value

Focused global distribution
Technology migration
25% segment share in 2006



imagination at work

PAGE 53
GE Healthcare RSNA
November 30, 2006

Global Compact Ultrasound

\$400MM global market growing 30%

5 new
compacts
in 2006

Traditional users (47%)

\$190MM

Cardiology
Radiology
Vascular
OB/Gyn

High-performance IQ
Common UI w/ consoles
Full-featured system
Console/compact solution



Vivid i



Voluson i



LOGIQ i

Serving the growing demand for
bedside & off-site imaging services

Emerging users (53%)

\$200MM

Surgery
Emergency
Anesthesia
Private office

Emerging & new users
Specialized applications
Console-level performance
Automated / easy to use



Vivid e



Voluson e



LOGIQ e

Bringing the benefits of ultrasound to
every clinician & patient



imagination at work


PAGE 54
GE Healthcare RSNA
November 30, 2006

Becoming #1 in Compact Ultrasound

GE Healthcare's
LOGIQ i



Compact Ultrasound revenue
(\$MM)



Seizing leadership in 2006 – critical success factors

- Clinically specialized products... 5 NPIs in 2006
- Specialized & dedicated distribution Rad / Card / OB/Gyn / EM / OR / Office
- Global U/S R&D → technology migration

Scale and
breadth a huge
advantage



imagination at work

Sources: Sonosite public information
GE internal


PAGE 55
GE Healthcare RSNA
November 30, 2006

Case study: anesthesiology nerve block


ID market trend

- \$150MM segment growing 30% per year
- U/S guidance for anesthesia nerve block injection
- New Std of Care O/R

Global U/S Guidance Market



Optimize product



- Proprietary CrossXbeam tech
- Image quality/size
- Ease of use
- App specific presets

Focus distribution

- 75 reps: largest in segment
- X-selling incentives to open the door
- Build luminary & advisory board excitement
- Host awareness & education programs... create market



imagination at work

PAGE 56
GE Healthcare RSNA
November 30, 2006

In summary...



Ultrasound

Cardiology

Monitoring

Bone
Densitometry

Maternal
Infant Care

Life
Support

- ✓ High performance portfolio
- ✓ Broad footprint in hospitals and clinic settings
- ✓ Market-aligned growth model
- ✓ Re-defining "the front door" of healthcare



PAGE 57
GE Healthcare RSNA
November 30, 2006

International: strategy for driving emerging growth markets



Reinaldo Garcia
President & CEO, GEHC International

RSNA Investor Meeting
November 30, 2006



International: terrific markets, great execution

(\$ in billions)

Revenue



Key messages

- ✓ Strong performance reflects tremendous potential of international markets
- ✓ Emerging markets growing faster than global average
- ✓ Highly skilled international talent base
- ✓ Company to country success strategy ... create demand and provide solutions




imagination at work

PAGE 59
GE Healthcare RSNA
November 30, 2006


Historical growth

(\$ in billions)

International revenue



International footprint



- \$7B+ international sales
- Emerging countries → Growth platform


✓ China	10-15%	✓ MEA	20-25%
✓ India	15-20%	✓ EE	15-20%
✓ SEA	20-25%	✓ LA	10-15%



imagination at work

PAGE 60
GE Healthcare RSNA
November 30, 2006

GE Healthcare global presence



imagination at work


Strong global commitment

PAGE 61
GE Healthcare RSNA
November 30, 2006

Growth in developed markets

(\$ in billions)

Japan




Key drivers

- Reimbursements ↓ ... ↑ high-end CT/MR
- Hospital consolidation and privatization
- IT investment trends and shift to digital

Winning position

- Enterprise and specialization ... DIC's, Cardio and Women's Health
- Strong combination of products, services and coverage

Western Europe



Key drivers

- PPP momentum in UK, Portugal, Germany and Italy
- EU focus on underperforming regions
- IT ... big growth area

Continued momentum

- Segmentation and commercial excellence
- Creating markets ... cardiac NM and screening
- Strong Services through NPS and segmentation




imagination at work

PAGE 62
GE Healthcare RSNA
November 30, 2006

Emerging markets = growth engines

(\$ in millions)



Diverse strategies for winning

SEA

Medical tourism...financing...region segmentation

India

High-end and value products...financing...private initiatives

Eastern Europe

Company to country...EU funding

Latin America

Value products... financing

MEA

Company to country...training...private initiatives

China

Rural health...value products...financing




imagination at work


PAGE 63
GE Healthcare RSNA
November 30, 2006

Healthcare spending and growth

Healthcare spend % of GDP



Emerging markets technology segment growth



imagination at work

Huge Healthcare Needs ...

↑ population w/o access to healthcare
Undeveloped healthcare infrastructure
Financing needs ... access to funding

Emerging Growth Drivers

Privatization trends ... entrepreneurs
New Infrastructure investments
Value technologies
Rural health

Go Big GE Opportunities

Company to Country
Co-operating with developing countries
through aid programs
Financing and equity investments

New 2006 projects

Namibia \$15MM

- Finnish loan to Namibia
- Partner with Namibia MOH
- Turnkey project

Bosnia \$14MM

- Korea loan to Bosnia
- Partner with Bosnia MOH
- 7 hospitals

Accelerating orders




GE Healthcare RSNA
November 30, 2006

Technology localization

LCC technical capability growth

Headcount	2002	2006
India	350	762
China	218	343
Hungary	20	109
Other	40	50
Total	628	1,264



- Local national leadership
- Driving local value product
- Growing marketing effort

Remote R&F Loqiqbook Super Value Rad Dash2500 CTe/CTe Dual HF Advantage Value MR




Strategy

Assembly

Components

Full systems

MFG + R&D



Imagination at work

PAGE 65
GE Healthcare RSNA
November 30, 2006

Emerging market growth solutions

Performance technologies ...

... to close healthcare access gaps



- ✓ Local design & build strategy
- ✓ Products tailored to markets
- ✓ Huge investment acceleration

China & India ... rural hospitals

- 50,000 clinics in China ... 1/3 to be upgraded
- Promote entrepreneurs in India

SEA ... coverage

- Indonesia ... go direct
- Capitalize on medical tourism

Africa ... MIC, tuberculosis, emergency ... HIV

- Leverage International aid
- Replicate Ghana experience

Middle East ... local presence

- Local capacity in Saudi
- Go direct in Algeria

Russia ... government programs

- Localize production

Value products 5X revenue growth by 2009

International summary



Key messages

- ✓ Strong performance reflects tremendous potential of international markets
- ✓ Emerging markets growing faster than global average
- ✓ Highly skilled International talent base
- ✓ Company to country success strategy ... create demand and provide solutions



PAGE 67
GE Healthcare RSNA
November 30, 2006

Healthcare IT: delivering the future of Healthcare




Vishal Wanchoo
President, Integrated IT Solutions

RSNA Investor Meeting
November 30, 2006



Healthcare IT: vehicle for healthcare transformation

(\$ in billions)



Key messages

- ✓ Breadth, depth and integrated offerings
- ✓ EMR: delivering improved clinical outcomes
- ✓ Best-in-class vendor/customer partnerships
- ✓ Tremendous market opportunity
 - Hospitals ~20% EMR
 - Physician Offices ~15% EMR



Imagination at work

PAGE 69
GE Healthcare RSNA
November 30, 2006

Healthcare IT critical to achieve...

...better patient care



An internist would need to read 20 articles a day, 365 days a year to keep up to date....


Intermountain model ..embed evidence based Guidelines into Caregiver workflow

Digital with improved clinical information


ADULT ANTIBIOTIC ASSISTANT

Radiology Findings	Examination	Completed
Aspiration	Chest 1 View	02/03/05 09:32
Identified Pathogens	Specimen, Site	Collected
None identified from Microbiology, Serology, Cytology or Pathology		

...at lower costs




National savings Of \$100+B using Rochester or Salt Lake model




Source: Dr. John Wennberg, The Dartmouth Atlas of Healthcare, March 16, 2006, Based on National Medicare Spending

The vision: improving patient care through information technology






Building a world-class HCIT business

- ~30% CAGR ... strong organic growth
- >1,500 facilities ... >35 countries




Healthcare IT growth strategy

	Opportunity	GE strategy	Market opportunity
Imaging 	Radiology RIS/PACS essential Data explosion...2 year payback	<ul style="list-style-type: none"> ✓ Increase offerings to existing customers ✓ Win new customers via differentiation ✓ Expand horizontally into cardiology, pathology etc 	50% global penetration \$2.5B market at 8% growth
Hospital 	Historically focused on physician order entry for patient safety	<ul style="list-style-type: none"> ✓ Partner with Intermountain Healthcare ✓ Use EMR to improve clinical outcomes 	US: 20% penetration EMR \$3B market 8% growth
Physician office 	Customers requesting integrated admin/clinical solutions	<ul style="list-style-type: none"> ✓ Offer enhanced applications to customer base to drive EMR 	US: EMR penetration 15% \$800MM market at 12% growth

Winning in Imaging IT

Service growth



- ✓ New customers
- ✓ Hardware upgrades
- ✓ Software refresh
- ✓ New applications



New offerings

Differentiated technology "Only GE"




Localized Radiology Information System .. Americas, Europe, China, Japan

+




Global PACS

+




Advanced applications

Horizontal expansion




Radiology PACS

+



Cardiology PACS
15% market growth
20% penetration

+



Pathology PACS
new markets

Market potential \$6B

Winning in hospitals: + Intermountain

IMHC: 30 years delivering better outcomes / costs via advanced IT

IMHC clinicians and GE engineers partnering to deliver GE EMR



Proven results with hundreds of evidence-based disease-specific protocols:

- Reduced readmissions
- Lower death rate
- Lower cost
- 22 Hospitals / 100 Clinics

GE and IMHC EMR: Delivering evidenced-based, decision support for doctors

Enhancing GE's EMR ... first release 2008

\$3-4B incremental market potential over 5-7 years

- IMHC protocols and decision support embedded in GE workflow
- Change management expertise
- Mitigated variability in decision-making



Imagination at work

PAGE 75
GE Healthcare RSNA
November 30, 2006


Winning in physician office

Market status/dynamics


- 15% EMR penetration
- Pay for performance spurs adoption
- Stark relaxation ..hospitals subsidize EMRs for physicians
- Physicians requiring single product : administrative + clinical (EMR)

\$5-7B market potential

GE administrative application



GE EMR



GE growth/win strategy

- Full complement of products... admin, EMR, EDI
- Integrated administrative/EMR product
- Best-in-class admin product - largest customer base
- Offer new EMR application
- Win new customers



Imagination at work

PAGE 76
GE Healthcare RSNA
November 30, 2006

GE IT partnerships ...collaborating to Re-imagine Healthcare



- Reduced medication errors by 82%
- Reduced physician time on non-clinical activities by 28%
- Length of hospital stay cut in half



- Reduced medication error rates using CPOE combined with barcode med charting



- Delivered additional \$171M in net revenues
- Decreased A/R days significantly



- Decreased nurse documentation time
- Improved patient documentation availability
- Reduced medical errors at Barger Clinic


Healthcare IT summary

Key messages

- ✓ Breadth, depth and integrated offerings
- ✓ EMR: delivering improved clinical outcomes
- ✓ Best in class vendor/customer partnerships
- ✓ Tremendous market opportunity
 - Hospitals ~20% EMR
 - Physician offices ~15% EMR




Life Sciences: a critical element of Re-imagining healthcare



Life Sciences: opportunity and a window into pharma

(\$ in billions)



Key messages

- ✓ Significant profit growth
- ✓ Winning in core and future growth markets
- ✓ Exciting market opportunities in proteins and bio-therapeutics
- ✓ Well-positioned to grow organically and inorganically
- ✓ Research tools today will be clinical tomorrow

Why Life Sciences?

- Key partner to pharmaceutical and diagnostic industries
- Early insight into future trends via R&D market
- Opportunity to deliver profitable products to the R&D market before the clinic
- Low risk position in new therapies, such as monoclonal antibodies, cell and gene therapy etc
- Technology leverage across GE businesses and markets



DNA and gene analysis




Drug development technology



Protein technology



Biological manufacturing



Biosensors

Expanding Protein Technology

Lab purification



>20000 systems sold
\$1B sales

Building in protein analysis: sample preparation



Tissue



Sample Prep



Separation



Characterization

Micro-fractionation
Key step in biomarker and diagnostic workflow

Nano-LC
Opportunity to strengthen our broad technology base

Mass Spectrometry

Segment opportunity (\$MM)

~\$322




Leadership in protein manufacturing



Segment opportunity (\$MM)

~\$1190



- Involved in 90% of biopharmaceutical processes
- 30 new products 2004-2007
- Increasing presence in vaccines

Manufacturing innovation



Segment opportunity (\$MM)

~\$100




- Enabling disposable biomanufacturing processes
- Reducing time to clinic
- Ideal for emergency vaccine manufacturing

Driving cell therapy opportunities

Expanding our biomanufacturing offering

- Manufacturing technology for all future biological therapies
- Already in Ph3 clinical trials with technology to manufacture cell-based cancer vaccines
- Ready market in R&D before clinical implementation
- Significant investment in new products



Focus on cord blood banking

- Significant public/private initiatives
- High value (\$20MM+) customers
- Synergies with imaging to provide complete workflow solutions



GMP Grade Media for cell purification




Enclosed systems for cell purification



Automated purification



Cryopreservation




Imaging to administer and track

Cellular Imaging: significant market opportunity

Pre-clinical: high content analysis



Cell Imaging INCell



HT Cell Analysis Reagents & tools






Image Analysis




Custom Products & Services



Clinical: digital pathology system




Automated Microscopy




Tissue Biomarkers



PACS



GUI



Hardware, software and reagent opportunities

Enhancing productivity in drug discovery

Research opportunities in systems biology

Life Sciences: summary

Key messages

- ✓ Significant profit growth
- ✓ Winning in core and future growth markets
- ✓ Exciting market opportunities in proteins and bio-therapeutics
- ✓ Well-positioned to grow organically and inorganically
- ✓ Research tools today will be clinical tomorrow



Healthcare Re-imagined: what it means today, what it means tomorrow




Dr William Clarke
Chief Technology & Medical Officer


RSNA Investor Meeting
November 30, 2006




Predict and diagnose: the tipping point confronting the "Big 6"



Cardiac disease
~\$400+B




Alzheimer's disease
~\$100+B




Colon cancer
~\$14+B

Breast cancer
~\$15+B



Diabetes
~\$131+B



Lung cancer
~\$5+B



✓ Finding disease earlier

✓ Leveraging the power of:

- Biology
- Chemistry
- Physics
- Engineering
- Genomics
- Informatics



imagination at work

We ARE doing this...


PAGE 87
GE Healthcare RSNA
November 30, 2006

The changing health agenda

WHO predicts **35 million** deaths from chronic disease in 2005
80% in low-mid income countries

We need tailored global health strategies to manage and limit the impact of these epidemics

The challenge of chronic disease



imagination at work

PAGE 88
GE Healthcare RSNA
November 30, 2006

Source: WHO Preventing Chronic Diseases October 05

On the road to better healthcare

Three clinical situations



Can find disease,
can find patient



Find disease,
probably find patient



Probably find disease,
can't find patient



imagination at work


PAGE 89
GE Healthcare RSNA
November 30, 2006

Can find disease, can find patient

Tomo Mammo



Colonography



imagination at work

Innovation can save more lives,
reduce costs, improve efficiency

PAGE 90
GE Healthcare RSNA
November 30, 2006


Can find disease, probably find patient

Diabetes



imagination at work

Cardiovascular disease



50% die after 1st heart attack


"For the first time, physicians are able to non-invasively diagnose heart disease in at-risk patients."

*Stanley Katz, Chief of Cardiology,
North Shore University Hospital, NY*

PAGE 91
GE Healthcare RSNA
November 30, 2006

Can probably find disease, can't find patient

Alzheimer's disease




Mild Cognitive Impairment converts to
AD at a rate of 10 to 15% a year




imagination at work

Lung cancer




PAGE 92
GE Healthcare RSNA
November 30, 2006

Throughout the history of the world, 50% of people who have reached 65 years of age are alive today




We need to find this patient...

1.3 billion smokers worldwide...
of which 44 million are in the US




We need to find this patient...

In vitro and in vivo diagnostics are crucial to earlier and better health



Combined cost burden of the "Big 6" = ~\$665 billion per year in the US alone


Cardiac disease	~\$400+B
Alzheimer's disease	~\$100+B
Colon cancer	~\$14+B
Breast cancer	~\$15+B
Diabetes	~\$131+B
Lung cancer	~\$5+B




Finding it earlier
Treating it more effectively

Improves outcomes,
makes economic sense...

Combined cost burden of the "Big 6" = ~\$665 billion per year in the US alone



Utilizing clinical capabilities to influence changes in the healthcare system




Earlier investment in healthcare saves lives and is cost-effective

To do it...

- ✓ Great technology...Chemistry, Biology, Physics, Engineering
- ✓ Understanding of clinical relevance
- ✓ Partnering with healthcare systems
- ✓ Powerful information systems
- ✓ Long-term vision



Summary



Joe Hogan

RSNA Investor Meeting
November 30, 2006






Why GE Healthcare wins

- ✓ Industry leading technology
- ✓ Unmatched global, product and services reach
- ✓ World-class execution and process rigor
- ✓ Growth through disease focus
- ✓ Success in emerging markets
- ✓ Delivering clinical efficacy and efficiency

GEHC: diagnostics, life sciences
and IT transforming Healthcare



imagination at work



imagination at work